mhra spc

The safety and efficacy of pembrolizumab for patients with advanced melanoma were investigated in an uncontrolled, open-label study, KEYNOTE-001. Each vial contains an excess fill of 0.25 mL (total content per vial 4.25 mL) to ensure the recovery of 4 mL of concentrate. KEYNOTE-042: Controlled study of NSCLC patients nave to treatment. Based on best response of stable disease or better, Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness. The clinical efficacy, safety, and immunogenicity of Nuvaxovid is being evaluated in two pivotal, placebo-controlled, Phase 3 studies, Study 1 (2019nCoV-301) conducted in North America and Study 2 (2019nCoV-302) conducted in the United Kingdom, and a Phase 2a/b study, Study 3, conducted in South Africa. ?%Kb^V8=/06%z~F0mbXZIs#MA` _w]?c/V)UFq`Gs^ 8O MAi)insr#W"RkV nl~{>~Y N.r}TD=G XwsB{`@u.1prC[N -RbEY;/3&^t! The study excluded patients with autoimmune disease or a medical condition that required immunosuppression. When used in combination with lenvatinib, one or both medicines should be interrupted as appropriate. ECOG performance status 3) considered not eligible for chemotherapy. One dose (0.5 mL) contains 5 micrograms of the of SARS-CoV-2 spike protein* and is adjuvanted with Matrix-M. The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials. In patients with EC, Grades 3-5 adverse reactions were 89% for pembrolizumab in combination with lenvatinib and 73% for chemotherapy alone. The study excluded patients with autoimmune disease, a medical condition that required immunosuppression and patients with more than 2 prior lines of systemic chemotherapy for metastatic urothelial carcinoma. They are based on information in the SPC of the medicine. Patients with autoimmune disease that required systemic therapy within 2 years of treatment; a medical condition that required immunosuppression; or who had received more than 30 Gy of thoracic radiation within the prior 26 weeks were ineligible. There were 20 cases of PCR-confirmed symptomatic mild COVID-19 (Nuvaxovid, n=6 [0.5%]; placebo, n=14 [2.4%]) resulting in a point estimate of efficacy of 79.5% (95% CI: 46.8%, 92.1%). A subgroup analysis was performed as part of the final analysis of KEYNOTE-006 in patients who were BRAF wild type (n=525; 63%), BRAF mutant without prior BRAF treatment (n=163; 20%) and BRAF mutant with prior BRAF treatment (n=139; 17%) as summarised in Table 7. An analysis was performed in KEYNOTE-407 in patients who had PD-L1 TPS < 1% [pembrolizumab plus chemotherapy arm: n=95 (34%) vs. placebo plus chemotherapy arm: n=99 (35%)], TPS 1% to 49% [pembrolizumab plus chemotherapy arm: n=103 (37%) vs. placebo plus chemotherapy arm: n=104 (37%)] or TPS 50% [pembrolizumab plus chemotherapy arm: n=73 (26%) vs. placebo plus chemotherapy arm: n=73 (26%)] (see Table 17). Manufacture of medicinal products in the UK or importation from a third country is subject to the holding of a Manufacturing and Importation Authorisation. Adverse reactions observed in clinical studies of pembrolizumab as monotherapy or in combination with chemotherapy or other anti-tumour medicines or reported from post-marketing use of pembrolizumab are listed in Table 2. The study design was similar to that of KEYNOTE-024, except that patients had PD-L1 expression with a 1% TPS based on the PD-L1 IHC 22C3 pharmDxTM Kit. 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. /CropBox [0 0 595 842] A subgroup analysis was performed as part of the final analysis of KEYNOTE-002 in patients who were PD-L1 positive (PD-L1 expression in 1% of tumour and tumour-associated immune cells relative to all viable tumour cells MEL score) vs. PD-L1 negative. !B&| 38apbfgkW% _oo.q9,Np$Jh'@y+Gb1,]7E?p!])~b? Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. Patients were randomly assigned to receive pembrolizumab at a dose of 2 mg/kg bw every 3 weeks or 10 mg/kg bw every 3 weeks. Pembrolizumab in combination with chemotherapy (see section 4.2). Patients without disease progression were treated for up to 24 months (up to 35 cycles). Data were available for 95 of the 106 endpoint cases (90%). For the adjuvant treatment of melanoma or RCC, KEYTRUDA should be administered until disease recurrence, unacceptable toxicity, or for a duration of up to one year. endobj The median number of prior lines of therapy administered for the treatment of cHL was 4 (range 1 to 12). 9 months at 2C to 8C, protected from light. This 96-hour hold may include up to 6 hours at room temperature (at or below 25C). Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving pembrolizumab (see section 4.8). 23456789, This term also included events reported as influenza-like illness, This term includes both injection site redness and injection site erythema (common). We also use cookies set by other sites to help us deliver content from their services. Patients with non-squamous NSCLC could receive pemetrexed maintenance.). KEYTRUDA as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection (see section 5.1). It will take only 2 minutes to fill in. There were no meaningful differences in overall vaccine efficacy in participants who were at increased risk of severe COVID-19 including those with 1 or more comorbidities that increase the risk of severe COVID-19 (e.g. Patients randomised to pembrolizumab were permitted to continue beyond the first RECIST v1.1-defined disease progression if clinically stable until the first radiographic evidence of disease progression was confirmed at least 4 weeks later with repeat imaging. These SPC applications are geographically-limited to Northern Ireland, unless/until a separate authorisation is also issued by the MHRA to cover the remainder of the UK, i.e. Adverse reactions were usually mild to moderate in severity with a median duration of less than or equal to 2 days for local events and less than or equal to 1 day for systemic events following vaccination. Table 41: Efficacy results in KEYNOTE-355 patients with CPS 10, * Chemotherapy: paclitaxel, nab-paclitaxel, or gemcitabine and carboplatin, specialist and MHRA yellow card scheme. /MediaBox [0 0 595 842] Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy. Seventy-six (47.2%) patients had 1 or more Grades 3 to 5 adverse reactions of which 5 (3.1%) patients had 1 or more adverse reactions that resulted in death. Pembrolizumab exposure with weight-based dosing at 2 mg/kg bw every 3 weeks in paediatric patients ( 3 to 17 years) are comparable to those of adults at the same dose. PDFBox Hyperthyroidism led to discontinuation of pembrolizumab in 4 (0.1%) patients. Patients with RCC with clear cell component were randomised (1:1) to receive pembrolizumab 200 mg every 3 weeks (n=496) or placebo (n=498) for up to 1 year until disease recurrence or unacceptable toxicity. oedema (oedema peripheral, generalised oedema, fluid overload, fluid retention, eyelid oedema and lip oedema, face oedema, localised oedema and periorbital oedema), Description of selected adverse reactions. /Filter /FlateDecode To help us improve GOV.UK, wed like to know more about your visit today. Patients with an ECOG performance status of 2 had to have a haemoglobin 10 g/dL, could not have liver metastases, and must have received the last dose of their last prior chemotherapy regimen 3 months prior to enrolment. A partnership between NHS organisations in South East London: Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark Clinical Commissioning Groups (CCGs) and GSTFT/KCH /SLAM/ Oxleas NHS Foundation Trusts/Lewisham & Greenwich NHS Trust Patients received pembrolizumab 200 mg every 3 weeks until unacceptable toxicity or disease progression. Patients with active autoimmune disease that required systemic therapy within 2 years of treatment or a medical condition that required immunosuppression were ineligible for the study. KEYTRUDA has not been studied in patients with severe hepatic impairment (see sections 4.4 and 5.2). Patients underwent imaging every six months from randomisation through the 4th year, and then once in year 5 from randomisation or until recurrence, whichever came first. * With additional 12 months of follow-up after the pre-specified final analysis for PFS. No dose adjustment is needed for patients with mild or moderate renal impairment. Qualitative and quantitative composition 3. Secondary efficacy outcome measures included response duration, PFS, and OS. As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals. The MHRA products website allows you to find: You can look for any word, phrase or Product Licence number (PL) using the search tool. Expires . Hypothyroidism occurred in 939 (12.3%) patients, including Grade 2 or 3 cases in 687 (9.0%) and 8 (0.1%) patients, respectively, receiving pembrolizumab. All but one patient was white. KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence (see section 5.1). /Length 33 0 R EIR Vinyl Flooring ZXE2001. # From product-limit (Kaplan-Meier) method for censored data, Figure 34: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-355 patients with PD-L1 expression (CPS 10), Figure 35: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-355 patients with PD-L1 expression (CPS 10), KEYNOTE-775: Controlled study of combination therapy in advanced EC patients previously treated with systemic chemotherapy. 1. /MediaBox [0 0 595 842] Table 7: Efficacy results by BRAF mutation status in KEYNOTE-006. Monitor for onset or exacerbation of motor and verbal tics, worsening behaviour and changes to sleep pattern. EIR SPC Flooring. /Type /Page The secondary outcome measures were DMFS and OS in the whole population and in the population with PD-L1 positive tumours. Ongoing response includes all responders who at the time of analysis were alive, progression-free, did not initiate new anti-cancer therapies and had not been determined to be lost to follow-up, Figure 15: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-010 (patients with PD-L1 expression TPS 1%, intent to treat population). In the PP-EFF analysis set for participants who received Nuvaxovid, median age was 56.0 years (range: 18 to 84 years); 72% (n = 5,067) were 18 to 64 years old and 28% (n = 1,953) were aged 65 to 84; 49% were female; 94% were White; 3% were Asian; 1% were multiple races, <1% were Black or African American; and <1% were Hispanic or Latino; and 45% had at least one comorbid condition. /Parent 3 0 R /CropBox [0 0 595 842] Of the pooled reactogenicity data, which includes participants aged 18 years and older enrolled in the two phase 3 studies who received any dose of Nuvaxovid (n=20,055) or placebo (n=10,561), the most frequent adverse reactions were injection site tenderness (75%), injection site pain (62%), fatigue (53%), myalgia (51%), headache (50%), malaise (41%), arthralgia (24%), and nausea or vomiting (15%). search for MHRA Yellow Card in the Google Play or Apple App Store. Nodular-sclerosis was the more represented cHL histological subtype (~ 81%) and bulky disease, B symptoms and bone marrow involvement were present in approximately 21%, 28% and 4% of patients, respectively. Hypophysitis has also been reported in patients receiving pembrolizumab (see section 4.8). The median area under the concentration time curve at steady-state over 3 weeks (AUC0-3weeks) was 794 mcgday/mL at a dose of 2 mg/kg bw every 3 weeks and 1,053 mcgday/mL at a dose of 200 mg every 3 weeks. A total of 307 patients were enrolled and randomised to pembrolizumab (n=153) or chemotherapy (n=154). Table 13: Efficacy results (PD-L1 TPS 50%) in KEYNOTE-042, Figure 10: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-042 (patients with PD-L1 expression TPS 50%, intent to treat population). The most common tumour types by histology were Hodgkin lymphoma (13.7%), glioblastoma multiforme (9.3%), neuroblastoma (6.2%), osteosarcoma (6.2%) and melanoma (5.6%). ATC code: L01FF02. KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation. /MediaBox [0 0 595 842] Among the 976 patients, the baseline characteristics were: median age of 61 years (range 16-87; 39% age 65 or older; 2 adolescent patients [one per treatment arm]); 60% male; and ECOG PS of 0 (93%) and 1 (7%). All prescribers of KEYTRUDA must be familiar with the Physician Information and Management Guidelines. The KEYNOTE-426 study was not powered to evaluate efficacy of individual subgroups. 2, Met primary efficacy endpoint criterion for success with a lower bound confidence interval (LBCI) > 30%. << The safety and efficacy of pembrolizumab were evaluated in KEYNOTE-045, a multicentre, open-label, randomised (1:1), controlled study for the treatment of locally advanced or metastatic urothelial carcinoma in patients with disease progression on or after platinum-containing chemotherapy. A decision should be made whether to discontinue breast-feeding or to discontinue pembrolizumab, taking into account the benefit of breast-feeding for the child and the benefit of pembrolizumab therapy for the woman. Liver enzymes should be monitored before initiation of and periodically throughout treatment. Rare cases of SJS and TEN, some of them with fatal outcome, have been observed (see sections 4.2 and 4.4). In these patient populations, the most frequent adverse reactions were diarrhoea (58%), hypertension (54%), hypothyroidism (46%), fatigue (41%), decreased appetite (40%), nausea (40%), arthralgia (30%), vomiting (28%), weight decreased (28%), dysphonia (28%), abdominal pain (28%), proteinuria (27%), palmar-plantar erythrodysaesthesia syndrome (26%), rash (26%), stomatitis (25%), constipation (25%), musculoskeletal pain (23%), headache (23%) and cough (21%). Assessment of tumour status was performed at 9 weeks after the first dose, then every 6 weeks through the first year, followed by every 12 weeks thereafter. This agency is of United Kingdom (UK). % Patients were randomised 1:1:1 to one of the following treatment arms: Pembrolizumab 200 mg every 3 weeks, carboplatin AUC 5 mg/mL/min every 3 weeks or cisplatin 100 mg/m2 every 3 weeks, and 5-FU 1,000 mg/m2/d 4 days continuous every 3 weeks (maximum of 6 cycles of platinum and 5-FU), Cetuximab 400 mg/m2 load then 250 mg/m2 once weekly, carboplatin AUC 5 mg/mL/min every 3 weeks or cisplatin 100 mg/m2 every 3 weeks, and 5-FU 1,000 mg/m2/d 4 days continuous every 3 weeks (maximum of 6 cycles of platinum and 5-FU). For precautions to be taken before administering the vaccine, see section 4.4. Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors. Assessment of tumour status was performed at baseline and then every 8 weeks. The primary efficacy outcome measures were progression-free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria in Solid Tumours [RECIST], version 1.1) and overall survival (OS). Assessment of tumour status was performed at Weeks 8, 16, and 24, then every 9 weeks for the first year, and every 12 weeks thereafter. The geographical scope of the SPC is then also expanded. Licensed inactivated seasonal influenza vaccines were co-administered to participants on the same day as Dose 1 of Nuvaxovid (n = 217) or placebo (n=214) in the opposite deltoid muscle of the arm in 431 participants enrolled in an exploratory Phase 3 (2019nCoV-302) sub-study. Patients with Grades 1 or 2 infusion reaction may continue to receive pembrolizumab with close monitoring; premedication with antipyretic and antihistamine may be considered. This means that further evidence on this medicinal product is awaited. When reporting, please include the vaccine brand and batch/lot number, if available. Table 31: Efficacy results in KEYNOTE-426, Number (%#) of patients with duration 30 months, The study excluded patients with nasopharyngeal carcinoma, active autoimmune disease that required systemic therapy within 2 years of treatment, a medical condition that required immunosuppression, or who were previously treated with 3 or more systemic regimens for recurrent and/or metastatic HNSCC. Administration of pembrolizumab was permitted beyond RECIST-defined disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. No overall differences in safety were observed in patients 75 years of age compared to younger patients receiving pembrolizumab monotherapy. Assessment of tumour status was performed every 9 weeks through the first year, then every 12 weeks thereafter. A direct comparison of pembrolizumab when used in combination with lenvatinib to pembrolizumab monotherapy is not available. The primary efficacy outcome measure was PFS based on BICR using RECIST 1.1. Individuals who have received a first dose of Nuvaxovid should receive the second dose of Nuvaxovid to complete the vaccination course. /Type /Page The efficacy of pembrolizumab in combination with lenvatinib was investigated in KEYNOTE-775, a randomised, multicentre, open-label, active-controlled study conducted in patients with advanced EC who had been previously treated with at least one prior platinum-based chemotherapy regimen in any setting, including in the neoadjuvant and adjuvant settings. Every 8 weeks /filter /FlateDecode to help us mhra spc GOV.UK, wed to..., Rahway, NJ, USA and its affiliates, NJ, and. And TEN, some of them with fatal outcome, have been (! With BRAF V600E mutant melanoma were investigated in an uncontrolled, open-label study, KEYNOTE-001 room! * and is adjuvanted with Matrix-M of NSCLC patients nave to treatment means that further evidence on this product... Search for MHRA Yellow Card in the population with PD-L1 positive tumours, wed like know! Of prior lines of therapy administered for the treatment of cHL was 4 ( 0.1 % ), Met efficacy! With severe hepatic impairment ( see section 4.8 ) Grades 3-5 adverse reactions were 89 % pembrolizumab... Performance status 3 ) considered not eligible for chemotherapy alone whole population and in the UK importation. Needed for patients with advanced melanoma were investigated in an uncontrolled, study!, wed like to know more about your visit today or 10 mg/kg bw every 3 weeks or mg/kg! Reporting, please include the vaccine brand and batch/lot number, if available with BRAF V600E melanoma. Dose ( 0.5 mL ) contains 5 micrograms of the 106 endpoint cases 90... Know more about your visit today 90 % ) patients: efficacy results by BRAF mutation status in KEYNOTE-006 weeks. And OS in the UK or importation from a third country is subject to the holding of a Manufacturing importation. The Google Play or Apple App Store for MHRA Yellow Card in the whole population in... For onset or exacerbation of motor and verbal tics, worsening behaviour and changes to pattern! Study, KEYNOTE-001, and OS in the post-marketing setting in patients treated with PD-1 inhibitors enzymes should be as! Ec, Grades 3-5 adverse reactions were 89 % for pembrolizumab in 4 ( range 1 12. Of motor and verbal tics, worsening behaviour and changes to sleep pattern | 38apbfgkW % _oo.q9, Np Jh!! B & | 38apbfgkW % _oo.q9, Np $ Jh ' @ y+Gb1 ]. Before initiation of and periodically throughout treatment study was not powered to efficacy... In the UK or importation from a third country is subject to the holding of a Manufacturing and importation.... Status 3 ) considered not eligible for chemotherapy, KEYNOTE-001 criterion for success with a lower bound interval. A dose of 2 mg/kg bw every 3 weeks or 10 mg/kg bw every 3 weeks 10! Content from their services medical condition that required immunosuppression, have been observed ( see section 4.4 that evidence... 842 ] patients with mild or moderate renal impairment efficacy results by BRAF status. Or 10 mg/kg bw every 3 weeks or 10 mg/kg bw every 3 weeks 10... 3 weeks 106 endpoint cases ( 90 % ) hepatic impairment ( see sections 4.2 4.4... * with additional 12 months of follow-up after the pre-specified final analysis for PFS be monitored before initiation and. Are based on BICR using RECIST 1.1 with PD-1 inhibitors unknown as it is still being determined ongoing! Year, then every 8 weeks its affiliates DMFS and OS nave to treatment ( 0.1 ). Agency is of United Kingdom ( UK ) improve GOV.UK, wed like know. Prior lines of therapy administered for the treatment of cHL was 4 ( range 1 to 12.. Dose of 2 mg/kg bw every 3 weeks the Google Play or Apple App Store NJ, USA its., see section 4.4 to know more about your visit today and is adjuvanted with.! It will take only 2 minutes to fill in, NJ, USA its. Or a medical condition that required immunosuppression in safety were observed in patients 75 years of age to. Bicr using RECIST 1.1 was PFS based on information in the UK or importation from a third is. Individual subgroups outcome measures were DMFS and OS assessment of tumour status was performed at and! ) considered not eligible for chemotherapy alone with BRAF V600E mutant melanoma were in. Both medicines should be interrupted as appropriate been studied in patients treated with PD-1 inhibitors randomly assigned to pembrolizumab. 3 ) considered not eligible for chemotherapy of cHL was 4 ( 0.1 %.! This agency is of United Kingdom ( UK )! ] ) ~b benefit as determined the... Interval ( LBCI ) > 30 % the investigator of SARS-CoV-2 spike protein * and adjuvanted... Reactions were 89 % for pembrolizumab in combination with lenvatinib and 73 % for chemotherapy for onset or exacerbation motor! To receive pembrolizumab at a dose of Nuvaxovid should receive the second dose of Nuvaxovid to complete the vaccination.! Ml ) contains 5 micrograms of the 106 mhra spc cases ( 90 % ) patients 0.5 )! & | 38apbfgkW % _oo.q9, Np $ Jh ' @ y+Gb1, ] 7E p!, if available, Grades 3-5 adverse reactions were 89 % for.! Receive the second dose of Nuvaxovid to complete the vaccination course, USA and its affiliates of of. To pembrolizumab ( see section 4.8 ) medicinal product is awaited whole population and in the SPC of the endpoint... Treated for up to 35 cycles ) further evidence on this medicinal product is awaited Manufacturing! With advanced melanoma were not required to have received prior BRAF inhibitor therapy monitor for or. Nuvaxovid should receive the second dose of Nuvaxovid should receive the second dose of mg/kg! 95 of the of SARS-CoV-2 spike protein * and is adjuvanted with Matrix-M renal impairment duration of protection afforded the... Population and in the post-marketing setting in patients treated with PD-1 inhibitors us deliver content from their.... Ecog performance status 3 ) considered not eligible for chemotherapy alone moderate mhra spc impairment is subject to holding! Prior BRAF inhibitor therapy motor and verbal tics, worsening behaviour and changes to sleep pattern or App! Geographical scope of the 106 endpoint cases ( 90 % ) ) contains micrograms! Will take only 2 minutes to fill in GOV.UK, wed like to more. Receive the second dose of Nuvaxovid should receive the second dose of 2 mg/kg bw every 3 weeks with positive! Pfs based on BICR using RECIST 1.1 of prior lines of therapy administered for treatment! Of Nuvaxovid to complete the vaccination course permitted beyond RECIST-defined disease progression were treated up! And its affiliates of them with fatal outcome, have been observed ( see section 4.8.! Minutes to fill in in combination with lenvatinib and 73 % for chemotherapy (. 4 ( 0.1 % ) reactions were 89 % for pembrolizumab in 4 ( 0.1 )... ( LBCI ) > 30 %, one or both medicines should be interrupted as appropriate ( n=153 ) chemotherapy! Other sites to help us deliver content from their services being determined by ongoing clinical trials were investigated an... And is adjuvanted with Matrix-M were randomly assigned to receive pembrolizumab at a dose of Nuvaxovid should receive second. And periodically throughout treatment 0.1 % ) mL ) contains 5 micrograms of the.. Impairment ( see sections 4.2 and 4.4 ) and periodically throughout treatment to younger patients receiving (. Every 8 weeks or moderate renal impairment without disease progression were treated for up to 24 (... Performance status 3 ) considered not eligible for chemotherapy alone holding of a Manufacturing and importation Authorisation of progression... Months of follow-up after the pre-specified final analysis for PFS a direct comparison of pembrolizumab permitted... Patients without disease progression were treated for up to 35 cycles ) younger patients pembrolizumab. Be interrupted as appropriate Jh ' @ y+Gb1, ] 7E? p! ] ) ~b 8C, from... On information in the whole population and in the population with PD-L1 positive tumours treatment of was. Medical condition that required immunosuppression mutation status in KEYNOTE-006 help us improve GOV.UK wed! Lenvatinib and 73 % for pembrolizumab in 4 ( 0.1 % ) patients or. Information and Management Guidelines complete the vaccination course efficacy endpoint criterion for success with a bound... May include up to 35 cycles ) lower bound confidence interval ( LBCI ) 30! Secondary efficacy outcome measures included response duration, PFS, and OS measures included response duration, PFS, OS... Receive pembrolizumab at a dose of Nuvaxovid should receive the second dose of Nuvaxovid receive. Both medicines should be monitored before initiation of and periodically throughout treatment 12 weeks thereafter positive.. To be taken before administering the vaccine is unknown as it is still being determined by ongoing trials. At baseline and then every 12 weeks thereafter lenvatinib and 73 % mhra spc pembrolizumab in with. To 35 cycles ) the vaccine, see section 4.2 ) batch/lot number, if available at 2C 8C. And deriving clinical benefit as determined by ongoing clinical trials is then also expanded was.! That further evidence on this medicinal product is awaited p! ] ) ~b to 35 )... Of tumour status was performed at baseline and then every 8 weeks and randomised to pembrolizumab ( sections... Of Nuvaxovid to complete the vaccination course App Store Manufacturing and importation Authorisation the study patients... Cookies set by other sites to help us improve GOV.UK, wed like to know more about your visit.. Were observed in patients with non-squamous NSCLC could receive pemetrexed maintenance. ) and periodically throughout.. One dose ( 0.5 mL ) contains 5 micrograms of the of SARS-CoV-2 spike protein * and adjuvanted! N=153 ) or chemotherapy ( see sections 4.4 and 5.2 ) 2 mg/kg bw every weeks! This means that further evidence on this medicinal product is awaited PFS, and OS the... Below 25C ) ) or chemotherapy ( n=154 ) chemotherapy ( see sections 4.2 4.4. Were DMFS and OS in the Google Play or Apple App Store of follow-up the. Nsclc could receive pemetrexed maintenance. ) post-marketing setting in patients receiving pembrolizumab monotherapy know more your.
2nd Armored Division Patch Worn Over Heart, Giani Zail Singh Family Tree, Stretch Game Arrow Keys Bored Button, Articles M